Stay updated with breaking news from Study Comparing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Media contact: Investor contact: ...
New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapse ...
The indication is for adult patients with multiple myeloma who are refractory to lenalidomide and have previously received at least 1 line of therapy.
New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapse ...
CARVYKTI® is the first CAR-T therapy for patients with relapsed and refractory multiple myeloma to receive a positive CHMP opinion for second line treatment ...